BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Orphazyme A/S: Major Shareholder Announcement - Nov. 16, 2017

  The company has received the following notifications pursuant to section 29 of the Danish Securities Trading Act regarding the existing major shareholders’ direct and indirect respective holdings of shares in Orphazyme.

  November 16, 2017

   · 

  9 min read
• Business

  Scott Vanderwel Joins PCI Synthesis as Business Development Manager Opens San Diego Office to Better Serve West Coast Emerging Pharma Sector

  VanderWel will lead sales and marketing efforts for the West Coast.

  November 16, 2017

   · 

  2 min read
• Policy

  Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD

  Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by Glaxo or one of its affiliates pursuant to its agreements with Innoviva.

  November 16, 2017

   · 

  8 min read
• Drug Development

  Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase II Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan

  Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa in the United States.

  November 16, 2017

   · 

  8 min read
• Pharm Country

  Teleflex Incorporated Announces Pricing of $500M Senior Notes Offering

  The sale of the Notes is expected to close on November 20, 2017, subject to customary closing conditions.

  November 16, 2017

   · 

  3 min read
• 

  Business

  Oncolytics Biotech, Adlai Nortye Forge $86.6M Reolysin Deal

  Under the terms of The Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan.

  November 16, 2017

   · 

  8 min read
• Business

  Lifeloc Reports Third Quarter 2017 Results

  The Company posted quarterly net revenue of $2.00 million for a quarterly net income of $190, or $0.00 per diluted share.

  November 16, 2017

   · 

  7 min read
• Drug Development

  Biohaven Completes Enrollment in the First of Two Pivotal Phase III Clinical Trials of Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist, for the Acute Treatment of Migraine

  Biohaven Pharma announced that it is completing enrollment today in the first of its two registrational Phase III clinical trials, Study BHV3000-301, to establish the safety and efficacy of orally-dosed rimegepant.

  November 16, 2017

   · 

  6 min read
• Business

  Evelo Biosciences and Mayo Clinic Collaborate to Advance Monoclonal Microbials for the Treatment of Inflammatory and Neuroinflammatory Diseases

  In the published studies, the monoclonal microbial, an anaerobic commensal microbe isolated from a human biopsy sample, led to a decrease in activity of Th17 inflammatory cells and an increase in the activity and frequency of regulatory T-cells.

  November 16, 2017

   · 

  3 min read
• Business

  Oxford Genetics Licenses SnapFast Expression Vectors to Twist Bioscience

  Oxford Genetics will supply Twist with its SnapFast technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.

  November 16, 2017

   · 

  3 min read